The ongoing COVID-19 pandemic greatly exposed a dearth of essential medications and significant vulnerabilities in the United States medical supply chain. Phlow Corporation aims to mitigate those weaknesses and manufacture essential generic medications at its Virginia manufacturing facility.
As one of the world’s top bio hubs, the BioHealth Capital Region (BHCR) is rife with life science assets. The region has been at the forefront of the SARS-CoV-2 vaccine race and it is rapidly becoming a center for advanced manufacturing. The BHCR cell and gene therapy ecosystem is thriving, and the area boasts one of the richest and most diverse tapestries of life science talent and workforce development programming. What’s more, Maryland, Washington, DC, and Virginia are home to several dynamic university systems that keep the talent and tech transfer pipeline humming and full.
BioFactura, Inc. today announced a contract option activation of over $13 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, as part of BioFactura’s prime contract
Pharmaceutical manufacturer Civica Inc. will invest $124.5 million to establish its first in-house pharmaceutical manufacturing operation in the City of Petersburg, VA. The project will create 186 new jobs.
5 Questions with Rachel Rath, MBA, MPH, Director, BARDA Alliance for Johnson & Johnson Innovation, JLABS @ Washington, DC
Rachel is the Director of the BARDA Alliance for Johnson & Johnson Innovation, based at JLABS @ Washington, DC. In this role, she is responsible for managing the BLUE KNIGHT™ collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA). BLUE KNIGHT™ focuses on addressing public-health threats and emerging infectious diseases by supporting companies with emerging science and technology solutions that aim to improve health security and responses.
Andrew Davis is Vice President at Scheer Partners and helps run the scientific real estate practice. Andrew lives in Maryland but assists scientific companies identify, negotiate, and build space in the Biohealth Capital Region, Philadelphia / Greater PA, and Massachusetts.